Enterostatin inhibition of angiogenesis: Possible role of pAMPK and vascular endothelial growth factor A (VEGF-A)

International Journal of Obesity

Volumn 32, Issue 6, 2008, Pages 922-929

  Park, M ^a   Lyons III, J ^b   Oh, H ^a   Yu, Y ^c   Woltering, E A ^b   Greenway, F ^c   York, D A ^a  

^a UTAH STATE UNIVERSITY   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

Angiogenesis; Human adipose tissue; In vitro assays; Veins

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ADENYLATE KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DISHEVELLED 1; ENTEROSTATIN; EPHRIN RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 12; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C ZETA; SECRETED FRIZZLED RELATED PROTEIN 4; VASCULOTROPIN A;

ADIPOCYTE; ADIPOSE TISSUE; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; NERVE CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TISSUE CULTURE; WESTERN BLOTTING;

ADENYLATE KINASE; AMINOIMIDAZOLE CARBOXAMIDE; ANGIOGENESIS INHIBITORS; BLOTTING, WESTERN; CELL LINE; COLIPASES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME PRECURSORS; GENE EXPRESSION; HUMANS; HYPOGLYCEMIC AGENTS; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RIBONUCLEOTIDES; RNA, MESSENGER; SUBCUTANEOUS FAT, ABDOMINAL; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 47249089073     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2008.16     Document Type: Article

References (35)

1. Lin L, Park M, York DA. Enterostatin inhibition of dietary fat intake is modulated through the melanocortin system. Peptides 2007; 28: 643-649.
2. York DA, Park MJ. Enterostatin, a peptide regulator of dietary fat ingestion. In: Kastan A (ed). Biologically Active Peptides. Elsevier Inc.: San Diego, CA, 2006, pp 969-974.
3. Okada S, York DA, Bray GA, Mei J, Erlanson-Albertsson C. Differential inhibition of fat intake in two strains of rat by the peptide enterostatin. Am J Physiol 1992; 262: R1111-R1116.
4. Okada S, York DA, Bray GA. Procolipase mRNA: tissue localization and effects of diet and adrenalectomy. Biochem J 1993; 292 (Part 3): 787-789.
5. Sorhede M, Mulder H, Mei J, Sundler F, Erlanson-Albertsson C. Procolipase is produced in the rat stomach - a novel source of enterostatin. Biochim Biophys Acta 1996; 1301: 207-212.
6. Lin L, Park M, Hulver M, York DA. Different metabolic responses to central and peripheral injection of enterostatin. Am J Physiol Regul Integr Comp Physiol 2006; 290: R909-R915.
7. Ookuma M, York DA. Inhibition of insulin release by enterostatin. Int J Obes Relat Metab Disord 1998; 22: 800-805.
8. Park M, , Lin L, Thomas S, Braymer HD, Smith PM, Harrison DH et al. The F1-ATPase beta-subunit is the putative enterostatin receptor. Peptides 2004; 25: 2127-2133.
9. Berger K, Sivars U, Winzell MS, Johansson P, Hellman U, Rippe C et al. ATP synthase - a direct target in appetite regulation and energy balance. Nutr Neurosci 2002; 5: 201-210.
10. Berger K, Sivars U, Winzell MS, Johansson P, Hellman U, Rippe C et al. Mitochondrial ATP synthase - a possible target protein in the regulation of energy metabolism in vitro and in vivo. Nutr Neurosci 2002; 5: 201-210.
11. Martinez LO, Jacquet S, Esteve JP, Rolland C, Cabezón E, Champagne E et al. Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature 2003; 421: 75-79.
12. Moser TL, Kenan DJ, Ashley TA, Roy JA, Goodman MD, Misra UK et al. Endothelial cell surface F1-F0 ATP synthase is active in ATP synthesis and is inhibited by angiostatin. Proc Natl Acad Sci USA 2001; 98: 6656-6661.
13. Moser TL, Stack MS, Asplin I, Enghild JJ, Højrup P, Everitt L et al. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci USA 1999; 96: 2811-2816.
14. Kim BW, Choo HJ, Lee JW, Kim JH, Ko YG. Extracellular ATP is generated by ATP synthase complex in adipocyte lipid rafts. Exp Mol Med 2004; 36: 476-485.
15. Das B, Mondragon MO, Sadeghian M, Hatcher VB, Norin AJ. A novel ligand in lymphocyte-mediated cytotoxicity: expression of the beta subunit of H+ transporting ATP synthase on the surface of tumor cell lines. J Exp Med 1994; 180: 273-281.
16. Neurath KM, Keough MP, Mikkelsen T, Claffey KP. AMP-dependent protein kinase alpha 2 isoform promotes hypoxia-induced VEGF expression in human glioblastoma. Glia 2006; 53: 733-743.
17. Ouchi N, Shibata R, Walsh K. AMP-activated protein kinase signaling stimulates VEGF expression and angiogenesis in skeletal muscle. Circ Res 2005; 96: 838-846.
18. Greenway FL, Liu Z, Yu Y, Caruso MK, Roberts AT, Lyons J et al. An assay to measure angiogenesis in human fat tissue. Obes Surg 2007; 17: 510-515.
19. Woltering EA, Lewis JM, Maxwell IV PJ, Frey DJ, Wang YZ, Rothermel J et al. Development of a novel in vitro human tissue-based angiogenesis assay to evaluate the effect of antiangiogenic drugs. Ann Surg 2003; 237: 790-798; discussion 798-800.
20. Hornick CA, Myers A, Sadowska-Krowicka H, Anthony CT, Woltering EA. Inhibition of angiogenic initiation and disruption of newly established human vascular networks by juice from Morinda citrifolia (noni). Angiogenesis 2003; 6: 143-149.
21. Brown KJ, Maynes SF, Bezos A, Maguire DJ, Ford MD, Parish CR et al. A novel in vitro assay for human angiogenesis. Lab Invest 1996; 75: 539-555.
22. Yun H, Lee M, Kim SS, Ha J. Glucose deprivation increases mRNA stability of vascular endothelial growth factor through activation of AMP-activated protein kinase in DU145 prostate carcinoma. J Biol Chem 2005; 280: 9963-9972.
23. Champagne E, Martinez LO, Collet X, Barbaras R. Ecto-F1Fo ATP synthase/F1 ATPase: metabolic and immunological functions. Curr Opin Lipidol 2006; 17: 279-284.
24. Lin L, Okada S, York DA, Bray GA. Structural requirements for the biological activity of enterostatin. Peptides 1994; 15: 849-854.
25. Nishimura S, Manabe I, Nagasaki M, Hosoya Y, Yamashita H, Fujita H et al. Adipogenesis in obesity requires close interplay between differentiating adipocytes, stromal cells, and blood vessels. Diabetes 2007; 56: 1517-1526.
26. Brakenhielm E, Cao R, Gao B, Angelin B, Cannon B, Parini P et al. Angiogenesis inhibitor, TNP-470, prevents diet-induced and genetic obesity in mice. Circ Res 2004; 94: 1579-1588.
27. Rupnick MA, Panigrahy D, Zhang CY, Dallabrida SM, Lowell BB, Langer R et al. Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci USA 2002; 99: 10730-10735.
28. Kim YM, An JJ, Jin YJ, Rhee Y, Cha BS, Lee HC et al. Assessment of the anti-obesity effects of the TNP-470 analog, CKD-732. J Mol Endocrinol 2007; 38: 455-465.
29. Voros G, Maquoi E, Demeulemeester D, Clerx N, Collen D, Lijnen HR. Modulation of angiogenesis during adipose tissue development in murine models of obesity. Endocrinology 2005; 146: 4545-4554.
30. Lijnen HR, Christiaens V, Scroyen I, Voros G, Tjwa M, Carmeliet P et al. Impaired adipose tissue development in mice with inactivation of placental growth factor function. Diabetes 2006; 55: 2698-2704.
31. Silha JV, Krsek M, Sucharda P, Murphy LJ. Angiogenic factors are elevated in overweight and obese individuals. Int J Obes 2005; 29: 1308-1314.
32. Rega G, Kaun C, Demyanets S, Pfaffenberger S, Rychli K, Hohensinner PJ et al. Vascular endothelial growth factor is induced by the inflammatory cytokines interleukin-6 and oncostatin M in human adipose tissue in vitro and in murine adipose tissue in vivo. Arterioscler Thromb Vasc Biol 2007; 27: 1587-1595.
33. Fain JN, Madan AK. Insulin enhances vascular endothelial growth factor, interleukin-8, and plasminogen activator inhibitor 1 but not interleukin-6 release by human adipocytes. Metabolism 2005; 54: 220-226.
34. Okada S, Lin L, York DA, Bray GA. Chronic effects of intracerebral ventricular enterostatin in Osborne-Mendel rats fed a high-fat diet. Physiol Behav 1993; 54: 325-329.
35. Lin L, Chen J, York DA. Chronic ICV enterostatin preferentially reduced fat intake and lowered body weight. Peptides 1997; 18: 657-661.